Skip to main content
Equibles
STTK logo

STTK · Shattuck Labs, Inc. · Investor Relations

Track STTK — free

Use STTK with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research STTK.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.01 +0.16 (+2.74%) At close · Sep 18
Russell 2000 member Rebalance outlook locked
Market Cap
$603.18M
Shares
100.36M

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-09-02 Shattuck Labs Announces Participation in Upcoming September Investor Conferences
2026-08-11 Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-06-10 Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering
2026-06-09 Shattuck Labs, Inc. Announces Proposed Public Offering
2026-06-09 Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update
2026-06-08 Shattuck Labs Announces Phase 1 Results for SL-325
2026-06-05 Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
2026-05-07 Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-03-05 Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights
2026-02-25 Shattuck Labs Announces Participation in Upcoming March Investor Conferences
2026-02-06 Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium
2025-12-15 Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Past events

Date Event Type
2026-09-09 Cantor Global Healthcare Conference Conference
2026-09-08 Wells Fargo 21st Annual Healthcare Conference Conference
2026-06-08 Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update Event
2026-03-02 TD Cowen 46th Annual Health Care Conference Conference
2026-02-12 Piper Sandler Virtual Novel Targets in Immunology Symposium Event
2025-10-08 Wedbush Securities Key Opinion Leader (KOL) and Company Panel Event
2025-04-09 24th Annual Needham Healthcare Conference Conference
2025-02-20 European Crohn’s and Colitis Organization (ECCO) Presentation Presentation
2025-02-08 2025 Crohn’s and Colitis Congress Event
2025-01-16 43rd Annual J.P. Morgan Healthcare Conference Conference
2024-12-04 7th Annual Evercore ISI HealthCONx Conference Conference
2024-12-03 Piper Sandler 36th Annual Healthcare Conference Conference
2024-10-01 Company Update and Announcement of SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Event
2024-08-05 BTIG Virtual Biotechnology Conference Conference
2024-06-14 Shattuck Labs EHA 2024 Conference Call Conference
2024-04-17 Citi's Biotech C-Suite Fireside Chat Series Event
2024-04-08 23rd Annual Needham Healthcare Conference Conference
2024-03-04 TD Cowen 44th Annual Health Care Conference Conference
2024-01-11 42nd Annual J.P. Morgan Healthcare Conference Conference
2023-12-13 Shattuck Labs ASH 2023 Conference Call Conference
2023-11-29 6th Annual Evercore ISI HealthCONx Conference Conference
2023-11-09 Shattuck Labs Q3 2023 Earnings Call Earnings call
2023-04-19 22nd Annual Needham Virtual Healthcare Conference Conference
2023-03-13 Oppenheimer 33rd Annual Healthcare Conference Conference
2023-03-06 Cowen 43rd Annual Health Care Conference Conference

Source: https://ir.shattucklabs.com/overview/default.aspx

Key facts CIK 1680367 CUSIP 82024L103 13F (30d) 3 filings 3 filers Visit website Investor relations